Leanne M. Rakers
Principal / St. Louis Metro Office
Leanne is a forward-thinking intellectual property attorney known for her creative approach to patent strategy and her dedication to mentoring the next generation of legal professionals. As the Practice Group Leader of the firm’s Chemical & Life Science practice group, she combines deep technical expertise with sharp legal insight to help clients navigate complex IP challenges.
Clients around the world value Leanne’s ability to identify patentable technologies and craft innovative, “outside-the-box” patent applications—especially in today’s evolving legal landscape, where patent eligibility is increasingly scrutinized. She delivers strategic counsel, practical solutions, and high-quality work with efficiency and precision. Beyond patent prosecution, her practice spans IP portfolio management, freedom-to-operate analyses, due diligence assessments, and FDA regulatory matters, including patent-drug FDA advising, Patent Term Extension applications, and Orange Book evaluations.
With a rare technical blend spanning chemistry, biotechnology, and life sciences, Leanne represents a diverse client base, from multinational corporations to startups in pharmaceuticals, biotechnology, biofuels, semiconductors, medical diagnostics, cosmetics, and food science. She has successfully protected innovations involving small molecule chemistry, biologics, pharmaceutical, cosmetic, and food formulations, therapeutic methods, organometallic chemistry, and recombinant DNA technologies. Her tenacity in securing patents has led to multiple victories on appeal before the USPTO.
A natural leader and mentor, Leanne is deeply committed to fostering growth within the legal profession. She previously served as Chair of the firm’s Diversity & Inclusion Committee, where she championed initiatives to empower diverse attorneys and expand opportunities in IP law. Known for her exceptional ability to teach and inspire, she dedicates time to helping colleagues and clients succeed, reinforcing her reputation as both a trusted advisor and a dynamic leader in the field.
Practice Areas
Industries
In the News
- “Patent Eligibility of Diagnostic Method Claims Following Proposed PERA Act of 2023,” Bloomberg Law
- 20 March 2024 USPTO Alert: USPTO ensures robust and reliable patents through examiner training on searching for prior art in FDA and NIH databases
- "Treatment of Antibody Claims in the U.S. After Amgen v. Sanofi" – IP Strategist
- Attorneys Discuss the Harness IP Diversity & Inclusion Fellowship with Michigan Lawyers Weekly
- "Is it in the public’s interest to have two similar cholesterol drugs on the market?" STAT, January 6, 2017
- "Changing the Profession, One Lawyer at a Time," Law Practice Today, March 14, 2016
- "Attorneys Note Legal Issues for 3D Printing of Drugs," Bloomberg BNA, November 12, 2015
- "The courts set a new record for rejecting software patents in 2014," Vox, November 17, 2014
- Harness IP Elects Six New Principals, January 8, 2013
Events
- Leanne Rakers to Present on the Basics of IP Law for Entrepreneurs
- St. Louis Patent Attorneys to Present at Petfood Forum
- Harness IP Principals to Present on “IP for a Competitive Advantage” at the AgChem Summit
presentations
- Conducted a variety of lectures on patent prosecution sponsored by the Swedish Patent Office in Stockholm, Sweden, on topics including the legislatively-enacted AIA and judicially imposed Supreme Court mandates
- Conducted a variety of seminars in Osaka, Japan in 2013 and 2014 on post-grant AIA strategies and chemical/biotech patent prosecution strategies
- Speaker at the 2014 Corporate Patent Seminar in Chicago, IL on recent USPTO patent office tools
Articles
- “Patent Eligibility of Diagnostic Method Claims Following Proposed PERA Act of 2023,” Bloomberg Law
- "Treatment of Antibody Claims in the U.S. After Amgen v. Sanofi" – IP Strategist
- Harness IP Attorneys Pen New Article about the Impact of USPTO Guidance Revisions on Biosimilars
- Leanne Rakers Pens Article on Protecting IP for Cosmetics Start-ups
- Leanne Rakers Shares Four IP Strategies for Cosmetics Innovators
Blogs
- U.S. Chemical & Life Science Patents Quarterly Newsletter
- 20 March 2024 USPTO Alert: USPTO ensures robust and reliable patents through examiner training on searching for prior art in FDA and NIH databases
- 25 September 2024 USPTO Coding Error Alert: Check your Patent Term Adjustment (PTA)!
- 1 October 2024 USPTO Alert: Extension and Termination of the After Final Consideration Pilot Program 2.0
- USPTO Guidelines on Enablement Requirement published 10 January 2024
- WIPO Standard ST.26 Tips as of 16 August 2022
- WIPO ST.26 Resources
- Features of WIPO Sequence
- ST.25 vs. ST.26 Sequence Listings
- WIPO ST.26 Overview
- FDA Publishes New Guidance Limiting Petitions that Could Delay Biosimilar Applications
- BioPharma Patents Quick Tips & News – March 2016 – Throwback Edition
- BioPharma Patents Quick Tips & News – January 2016 – Throwback Edition
- BioPharma Patents Quick Tips & News – September 2015 – Throwback Edition
- BioPharma Patents Quick Tips & News – July 2015 – Throwback Edition
- FDA Implements Biosimilar Action Plan to Boost Biosimilar Competition
- BioPharma Patents Quick Tips & News – May 2015 – Throwback Edition
- BioPharma Patents Quick Tips & News – March 2015 – Throwback Edition
- BioPharma Patents Quick Tips & News – January 2015 – Throwback Edition
- Updated Examination Procedure For 101 Rejections Announced in USPTO Berkheimer Memo
- BioPharma Patents Quick Tips & News - November 2017
- BioPharma Patents Quick Tips & News – November 2014 – Throwback Edition
- BioPharma Patents Quick Tips & News – July/August 2014 – Throwback Edition
- Chemistry & Nanotechnology Developments to Watch in 2017
- SCOTUS to Weigh In on Two Biosimilar Provisions of the BPCIA in 2017
- Harnessing the Innovation of BioPharma
- BioPharma Patents Quick Tips & News – May/June 2014 – Throwback Edition
- BioPharma Patents Quick Tips & News – January/February 2014 – Throwback Edition
- BioPharma Patents Quick Tips & News – October 2016
- BioPharma Patents Quick Tips & News – November/December 2013 – Throwback Edition
- BioPharma Patents Quick Tips & News – July 2016
- BioPharma Patents Quick Tips & News – January 2016
- BioPharma Patents: Quick News & Practice Tips – November 2015
- The December Sequel to the USPTO’s March Guidance
- BioPharma Patents Quick Tips & News - January/February 2014
- BioPharma Patents Quick Tips and News - November/December 2013
Prior to practicing law, Leanne studied cell cycle inhibitors and suppressors of cytokine signaling at Pennsylvania State University and GlaxoSmithKline Pharmaceuticals. She subsequently focused on recombinant protein expression at Sigma-Aldrich Corporation, and is a co-inventor of U.S. Patent No. 6,902,914 (Recombinant DNA Processes Using A dNTP Mixture Containing Modified Nucleotides).
An invited speaker in the U.S. and abroad, Leanne educates both clients and colleagues on the nuances of patent prosecution and enforcement strategies. Her passion for the America Invents Act (AIA) has spawned many presentations across the U.S., Europe and Japan.
awards & Distinctions
- St. Louis Business Journal 40 Under 40 Class of 2016
- Missouri Lawyers Weekly “Up and Coming Lawyer,” 2013
Memberships
- Chemical & Life Science Practice Group Leader
- Harness IP Diversity & Inclusion Committee, Former Chair
- Intellectual Property Owners Association, Pharmaceutical & Biotechnology Issues Committee, Women in IP Committee
- American Intellectual Property Law Association
Education
J.D., Washington University in St. Louis, 2005
B.S., Microbiology, cum laude, Pennsylvania State University, 2000
Bar & Court Admissions
Missouri
U.S. Court of Appeals for the Federal Circuit
U.S. Supreme Court
U.S. Patent and Trademark Office